



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

08 Nov 2021 (#37)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

Eligibility Requirements for Foreign Investigators and Institutions: Applications from foreign institutions are strengthened when they include either expertise, study opportunities, or resources that are not easily available in the United States—for example, access to a unique study population or scientists with unusual skills or achievements.

Know What Interim Paylines Mean for NIAID Awards: NIAID posted interim fiscal year 2022 [paylines](#) for research projects.

As a reminder, NIH will transition from the FORMS-F application form set to a new FORMS-G application form. Find resources updated for FORMS-G at [How To Apply—Application Guide](#) and [Annotated Form Sets](#)

NOT-AG-22-001: NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice. The National Institute on Aging (NIA) Interventions Testing Program (ITP) was established to test compounds purported to extend lifespan and/or delay the onset of disease and disability. The NIA ITP tests such compounds in mice, using a variety of measured endpoints to assess the efficacy of interventions. There are three sites that perform the testing, one at the University of Michigan, one at the University of Texas Health Sciences Center-San Antonio, and one at The Jackson Laboratory. It is anticipated that approximately 5 compounds will be accepted for study in 2023. The NIA ITP is soliciting proposals for compounds to enter the study in 2023. This is not a funding opportunity announcement, but rather a solicitation of suggestions for compounds to be tested in the ITP. The deadline for receipt of proposals is February 28, 2022. Information on the NIA ITP and guidelines for proposal development are posted at: <https://www.nia.nih.gov/research/dab/interventions-testing-program-itp>.

Effective immediately, the following section of [RFA-CA-21-047](#), "Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)" has been modified, as indicated: Non-domestic (non-U.S.) Entities (Foreign Institutions) **are eligible** to apply.

[NOT-TW-21-008](#) Notice of Intent to Publish a Funding Opportunity Announcement for Implementation Research for Chronic Disease Prevention Across the Lifespan (R01 Clinical Trial Optional). The Fogarty International Center (FIC) and partner National Institutes of Health (NIH) Institutes and Centers (ICs) have reorganized NIH participation in the [Global Alliance for Chronic Diseases](#) (GACD) and intends to publish Funding Opportunity Announcements (FOAs) that will utilize yearly Notices of Special Interest (NOSIs) to invite applications for implementation research on noncommunicable diseases (NCDs) in [World Bank-defined low- and middle-income countries](#) (LMICs) and marginalized Native American/Alaska Native populations in the United States.

Notices of Special Interest

[NOT-CA-22-001](#): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. The purpose of this Notice of Special Interest (NOSI) is to encourage collaborative and innovative approaches to mitigate cardiovascular dysfunction while optimizing cancer outcomes by understanding the mechanisms of cancer treatment-related cardiotoxicity and translating the findings to improve risk stratification, early detection, prevention, and management. This notice applies to due dates on or after February 5, 2022, and subsequent receipt dates through November 06, 2024. Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissues of these announcements

[PA-20-183](#) - NIH Research Project Grant (Parent R01 Clinical Trial Required)

[PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

[PAR-20-052](#) - NCI Small Grants Program for Cancer Research (R03 Clinical Trial Optional)

[PAR-20-077](#) - NCI Program Project Applications (P01 Clinical Trial Optional)

[PAR-20-292](#) - NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

[PAR-21-035](#) - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

[PAR-21-190](#) - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

[PAR-21-329](#) - Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

[PAR-21-341](#) - Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

Funding Opportunity Announcements (FOA)

1. Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-053](#)

Type: U01

Application Due Date: February 05, 2022; June 05, 2022; October 05, 2022 through to 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Functional Neurological Disorders (FNDs) are characterized by symptoms of altered voluntary motor or sensory function with clinical findings providing evidence of incompatibility between the symptoms and recognized neurological or medical conditions. FNDs are highly prevalent and associated with significant morbidity, health care costs, and even mortality. In some respects, this group of conditions sits at the intersection of neurology and psychiatry, but the majority of cases first come to the attention of neurologists. Management is complex and requires interdisciplinary approaches. Given the disability caused by the symptoms, and the high cost in healthcare utilization and loss of productivity, FNDs amount to a significant missed opportunity for therapeutic intervention and therefore, a healthcare crisis. Diagnosis and management of FNDs remain very challenging. Diagnostic criteria have been proposed but they are not universally agreed upon. Diagnosis is based on positive clinical findings, and can be supported by laboratory or ancillary investigation findings. Certain FND subtypes are more difficult to correctly diagnose than others. More importantly, laboratory-supported diagnosis is possible, and biomarkers can be developed, but significantly more research is needed in these areas to advance clinical management of FNDs. Therapies exist and have been studied in select populations but gathering high-level evidence through clinical trials is hampered by limitations in available outcome measures. Differential responses to treatments have been recorded, and thus, prediction of aggregate treatment response has been difficult.

This FOA invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this FOA include the validation of biomarkers, endpoints and clinical outcome assessments (COA) that are fit-for-purpose and have a defined context of use for clinical trials. Projects involving biomarker discovery or early validation should apply to the relevant FOAs ([PAR-19-315](#), [PAR-21-056](#), [PAR-21-057](#), [PAR-21-058](#), [PAR-21-059](#)). The initiative will promote partnerships among academic investigators, industry, and patient groups, and will encourage interactions with the Food and Drug Administration (FDA).

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum request cannot exceed 5 years but the actual funded project period is dependent on reaching specific milestones as described in this FOA.

2. Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-054](#)

Type:

Application Due Date: February 23, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as epigenomic assays of tumor or affected tissue, when justified. These data, and associated clinical and phenotypic data, will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Budget: Not Applicable; there are no funds associated with a resource access award. The scope of the proposed project should determine the project period. The maximum project period is 1 year.

3. Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-061](#)

Type: R01

Application Due Date: February 05, 2022; June 05, 2022; October 05, 2022 though to October 05, 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application. **Companion Funding Opportunity:** [PAR-22-062](#), [R21 Exploratory/Developmental Grants](#)

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. RePORT International Coordinating Center (RICC) (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-21-078](#)

Type: U01

Application Due Date: March 17, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center (RICC) for the national RePORT networks, whose mission is to advance regional and international TB and TB/HIV science, strengthen TB/HIV research capacity and infrastructure, and foster research collaboration. The RICC will coordinate the planning and implementation of research in TB and TB/HIV across all the RePORT networks and establish and maintain the required infrastructure to enable such research.

Budget: NIAID intends to commit \$4.0M in FY 2023 to fund one award. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project duration. The maximum project period is 5 years.

5. Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-22-003](#)

Type: R61

Application Due Date: April 22, 2022; September 22, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored [Innovative Molecular Analysis Technologies](#) (IMAT) Program. **Companion Funding Opportunity** [RFA-CA-22-004](#), [R33 Exploratory/Developmental Grants Phase II](#)

Budget: NCI intends to fund an estimate of 4 awards, corresponding to a total of \$1,000,000, for the fiscal year 2023. Future year amounts will depend on annual appropriations. Direct costs are limited to \$150,000 per year. Application budgets need to reflect the actual needs of the proposed project. The total project period request may not exceed 3 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: Christa
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: Lizel
e: lizelk@sun.ac.za | t: +27 21 808 2105